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Summary The localisation of tumour deposits by a 131 1 labelled monoclonal antibody to carcinoembryonic
antigen (CEA) has been evaluated in 24 patients with primary gastric, oesophageal and colorectal cancer and
in 26 patients with clinically suspected recurrent gastric and colorectal cancer. Seventeen of 20 primary sites
and 6/15 associated secondary sites were correctly identified by external scanning. Measurement of
radiolabelled antibody in the resected specimens demonstrated a 2.6-3.3 fold increase in comparison with the
surrounding normal tissue (P<0.01). The antibody scans were compared with computerised tomography (CT)
in the detection of recurrent disease. The respective sensitivities and specificities for the two investigations
were 61% and 33% for antibody scanning and 64% and 100% for CT. Assessment of the distribution of
labelled antibody demonstrated rapid clearance with <2% detectable in serum samples at 24h. The
implications of these findings together with the mechanisms ofexcretion are discussed.
Radioimmunolocalisation (RIL) has the potential
to specifically differentiate between malignant and
benign tissues. Studies in gastrointestinal cancer
with antibodies to CEA have demonstrated correct
identification in nearly 90% (Goldenberg et al.,
1980) and 42% (Mach et al., 1980) of tumour sites.
The variation between these series reflects
differences in the subjective interpretation of the
scans. In addition in these early studies polyclonal
antibodies were investigated which are limited by
cross-reactivity with similar antigens present in
normal tissues. The development of monoclonal
antibodies (Kohler & Milstein, 1975) has produced
agents with theoretically greater specificity for the
antigens and thus reduce the difficulties of cross-
reactivity. In this study we describe our experience
with a radiolabelled monoclonal antibody to CEA
together with its potential clinical application for
the staging of primary gastric and colorectal cancer
and for the detection of recurrent cancer. Previous
studies have suggested that the actual amount of
antibody accumulated in tumours is an extremely
small proportion of the amount injected (Mach et
al., 1981) and we have also assessed the distribution
of labelled antibody in patients and measured the
concentration of antibody within resected tumours.
Materials and methods
Preparation oflabelled antibody
Monoclonal antibody 11-285-14 is an IgG1 which
was prepared in a collaborative project between the
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Surgical Immunology Unit of the Queen Elizabeth
Hospital and Eli Lilly by conventional methods
against CEA extracted from liver metastases from a
colorectal carcinoma (Woodhouse, 1982). Extensive
characterisation has shown reaction with some
normal and the majority of malignant gastro-
intestinal epithelium (Hockey et al., 1984, Crowson
et al., 1984) but no reactivity with a wide range of
other normal tissues. In addition there is no
reactivity with granulocytes, red blood cells,
peripheral blood lymphocytes or chronic myeloid
leukaemic cells. Animals studies with colorectal
cancer xenografts in nude mice have demonstrated
preferential accumulation of labelled antibody in
tumours when compared with a control non-
specific antibody (unpublished observations, Pimm
et al., 1985b).
Approximately 500 g of antibody solution were
labelled with 5mCi of 131 Iodine by the chloramine
T method to a mean specific activity of 2.34,uCi/,ug.
(Hunter & Greenwood, 1962). All labelled
preparations were tested for sterility and the
absence of pyrogens prior to administration to
patients. In addition anti-CEA activity was assessed
after labelling by an enzyme linked immunosorbent
assay (ELISA) (Woodhouse et al., 1981) and by
indirect immunoperoxidase staining (Heyderman &
Neville, 1977) and demonstrated a mean percentage
loss in activity of 10%.
Patients
The details of the 50 patients investigated are
shown in Table I. The diagnosis of primary disease
was by conventional methods and of recurrent
disease either by the development of new symptoms
or an elevated serum CEA level. All patients gave
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Table I Distribution of patients entered into the study
by type ofcondition
Staging ofprimary disease 24
Gastric adenocarcinoma 10
Colorectal adenocarcinoma 11
Oesophageal squamous cell carcinoma 3
Detection of recurrent disease 26
Gastric cancer 10
Colorectal cancer 16
informed consent prior to entry into the study.
Potential hypersensitivity to the monoclonal anti-
body was tested by i.d. injection of 10 pg of
antibody in normal saline which was assessed at
30min and 24h. Potassium iodide 60mg TDS was
given 24h prior to administration of the labelled
preparation and continued for a week in order to
block thyroid uptake. Potassium perchlorate 200mg
QDS was given in the 24h prior to the first scan
and continued until after the second scan in order
to block nonspecific uptake of the 99 m Technetium
labelled preparations by the stomach or salivary
glands which were used for subtraction imaging
(Bradwell et al., 1983).
Administration of the labelled preparation was
always undertaken as an in-patient procedure. Anti-
body solution containing 200 pg antibody was
diluted in 100ml normal saline and infused over
30min. Patients were subsequently monitored in the
first 24h for adverse systemic effects.
Gamma camera scanning
Patients underwent scanning on a CGR Gamma
Tome 9000 gamma camera 24 and 48h after
antibody administration. This camera incorporates
a medium energy collimator which has a large field
of view. 99mTechnetium labelled pertechnetate and
human serum albumin were administrered to
patients just before scanning in order to estimate
the background blood pool activity. Antero-
posterior and posteroanterior views of the chest and
abdomen were the principle scanning views under-
taken but lateral views of either the chest or
abdomen were also taken when indicated. Each
view was scanned for 5min to allow accumulation
of sufficient activity. The scans were analysed by
computer, firstly by subtracting the background
blood pool activity represented by the Technetium
images and secondly by a thresholding technique
which allowed for statistical fluctuations in the
counts or noise such that any counts recorded were
deemed statistically significant (Fairweather et al.,
1983a).
The scans were interpreted by one investigator
(WHA) who had prior knowledge of the suspected
extent of the disease in the primary tumours but, in
the assessment of recurrent disease, had details
from the clinical presentation only. All patients
with primary disease underwent laparotomy 72h
following antibody administration when definitive
surgery was undertaken. Patients with suspected
recurrent disease also underwent computerised
tomography and the results have been compared
with the localisation scans. The results of both
techniques were confirmed or refuted either by
second look laparotomy or by review of subsequent
clinical progress.
Examination ofresected specimens
The radioactivity in samples of normal stomach or
colon, tumour, lymph nodes and apparently normal
tissues incidentally removed was measured in a well
gamma counter (Nuclear Enterprises Scaler/Rate-
meter SR7). In addition the complete specimen was
scanned with the gamma camera.
In order to estimate the concentration of
antibody within samples of the resected tumours,
tumour tissue was homogenised in the presence of
lysing buffer (20mm TRIS, 100mm NaCl, 1 mM
EDTA and 0.5nonidet P-40 pH8) and the antibody
extracted by Sepharose-Protein A absorption. The
concentration of antibody in the resultant
suspension was determined by an ELISA. The total
amount in the tumour was then estimated from the
dimensions of the whole tumour.
Evaluation ofvascular distribution and excretion
The intravascular distribution of the radiolabelled
antibody has been assessed by estimating the
circulating radioactivity and by measuring the
circulating concentration of antibody at 6, 24, 48
and 72h. Radioactivity within 10ml samples of
whole blood was measured and the activity in the
total blood volume calculated and expressed as a
percentage of the injected dose. The concentration
of the antibody in serum was measured using an
ELISA (as in the estimation of the concentration of
the tumour samples).
Excretion of radioactivity in both urine and
faeces was estimated for 24h periods and expressed
as a percentage of the injected amount of radiation.
Results
Adverse reactions
Significant responses to the i.d. injection (tenderness
and erythema greater than 1 cm in diameter) were
observed in 3 patients at 24h. These patients didLOCALISATION OF GASTROINTESTINAL CANCER
Table II Results of scanning in patients with primary gastric,
colorectal and oesophageal carcinoma
Positive Additional
scans activityc
Gastric cancer Primary sitesa 9 7 2
(n= 10) Secondary sites 8 3
Colorectal Primary sites' 8 7 0
cancer (n=10) Secondary sites 5 2
Oesophageal Primary sites 3 3 1
cancer (n=3) Secondary sites 2 1
aOne patient had a gastric volvulus and a true negative scan; bTwo
patients had either benign disease (acutely inflamed diverticular mass) or
normal laparotomy findings (despite an abnormal barium enema) had
false positive scans; cActivity in an area proven not to be involved at
laparotomy.
not receive the labelled preparation because of the
risk of hypersensitivity.
During infusion 2 patients had a transient
decrease in mean arterial blood pressure of
20 mmHg with an associated rise in pulse rate from
80 to 100 beats min-'. Three further patients had
persistent temperature rises up to 37.5°C for up to
5 h in the initial 24h after injection. Neither of
these patients complained of any associated
symptoms. Thus although no major reactions were
encountered, it is suggested that all patients are
carefully assessed for possible allergy to the mouse
protein before receiving the labelled antibody.
Antibody scanning in primary disease
The results of the scans in the 23 patients with
suspected primary gastric, colorectal or oesophageal
cancer are shown in Table II (one patient was
excluded because of possible hypersensitivity).
Malignant disease was confirmed at laparotomy in
20 patients and antibody scanning correctly
identified 17 of the primary tumours. Fifteen
patients had secondarily involved sites, 6 of which
were positively detected. Secondary nodal sites
which were not detected were <2cm in diameter.
Three primary lesions were not identified, two were
obscured by overlying heart and bladder activity.
The third primary lesion which was also apparent
on the Technetium scan disappeared from the
antibody scan after subtraction. In 3 patients
additional areas of activity consistent with tumour
were not confirmed at laparotomy.
There were 3 patients who were considered pre-
operatively to have cancer but laparotomy
consequently showed no evidence of malignant
disease. One patient with gastric volvulus, whose
barium meal had suggested a pyloric neoplasm, had
an unequivocally negative antibody scan. Two
patients in the colorectal group, however, had
positive scans but at laparotomy one had an acute
diverticular mass and the other had no abnormality
despite barium enema appearances of an
obstructing carcinoma.
A typical scan from a patient with transverse
colon cancer with spread to a local lymph node is
shown in Figure 1. The unsubtracted antibody scan
shows increased activity in the upper abdomen.
After thresholding there was an additional area of
activity considerably smaller than the main lesion
which was considered to be consistent with lymph
node metastases. At laparotomy the primary lesion
was confirmed, as was a 4cm diameter lymph node
deposit in the transverse mesocolon.
Antibody scanning in the detection ofrecurrent
cancer
Twenty of the 24 evaluable patients (2 were
excluded because of a significant skin reaction) had
recurrent disease confirmed in 23 sites by second
look laparotomy (n= 12) or by review of clinical
progress (n= 12).
Antibody scanning and CT each identified 14
sites correctly but equally failed to detect 9 and 8
sites respectively (Table III). The majority of the
sites that were missed were small deposits, although
Table Ill Results of antibody scanning and CT in
the detection of sites of recurrent gastric and
colorectal cancer
Antibody Computerised
scanning tomography
True positive 14 14
True negative 2 4
False positive 4 0
False negative 9 8
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Figure 1 Antibody scan ofthechest and upperabdomen ofapatient with a node positive transversecolon cancer.
(a) 99mTc scan, (b) 13ll scan, (c) subtraction scan and (d) threshold scan. Markers (x) represent the costal margin.
H =heart, L=liver, T =tumour and LN =lymph node. (Reproduced by kind permission of Surgery Annual.
in 2 cases bulky local recurrences were later
removed at second look laparotomy. Four patients
free of disease were correctly identified by CT,
however antibody scanning suggested that 2 of
these had recurrence. In a further 2 patients
antibody scanning correctly identified recurrence
but also suggested deposits in sites which were not
later confirmed.
Antibody scanning did detect disease in 2
patients which was not visible on CT scanning. One
patient, who had undergone a gastrectomy 18
months previously for a node positive tumour, was
investigated for recurrent symptoms. CT demon-
strated ascites only whereas antibody scanning
demonstrated uptake in both the liver and the
original left hypochondrial incision (Figure 2).
This patient rapidly developed clinical evidence of
hepatic metastases and aspiration cytology of the
original incision revealed adenocarcinoma cells. The
second patient had undergone a Hartmann's
procedure for a perforating carcinoma of the colon
and had returned for reversal of his colostomy. CT
was normal but antibody scanning revealed activity
low in the pelvis which at laparotomy was
confirmed to be due to many small deposits within
the pelvic peritoneum and omentum.
Comparison of these two techniques demon-
strates similar sensitivities (Table IV). The rela-
tively high false positive rate of the antibody
scan however indicates limited specificity which is
further reflected in the poor predictive value of a
negative test.LOCALISATION OF GASTROINTESTINAL CANCER 207
Table V Mean ratios of tumour to normal tissue activity
(normal tissue from corresponding organ) for primary and
secondary sites
Secondary site
Primary site (Lymph node)
Gastric
cancer 2.6:1 (P<0.01)a 2.7:1 (P<0.01)
Colorectal
cancer 3.3:1 (P<0.01) 2.5:1 (NS)
Oesophageal
cancer 1.7:1 (NS) 0.8:1 (NS)
aWilcoxon paired test.
Figure 2 Antibody scan (a) and CT scan (b) of a
patient with recurrent gastric cancer in the liver and
the left oblique hypochondrial incision. L=liver
metastatic activity, T=tumour site and B=urinarv
bladder. Panels a, b, c and d as in Figure 1. (Reproduced
by kind permission of Surgery Annual.)
Table IV Comparison of the values of antibody scanning
and computerised tomography in the detection of
recurrent gastric and colorectal cancer
Antibody Computerised
scanning tomography
Sensitivity 61% 64%
Specificity 33% 100%
Predictive value
of positive test 78% 100%
Predictive value
of negative test 18% 33%
Examination ofthe resected specimens
The radioactivity in samples of the resected tumour
was consistently higher than in surrounding normal
stomach or colon, or non CEA expressing tissues
(Table V). Accumulation of activity by the
oesophageal lesions was not significantly greater
than surrounding normal oesophageal tissue.
The uptake of activity by histologically involved
lymph nodes was significantly greater than in
normal lymph nodes removed with specimens of
gastric cancer (Table V). Those lymph nodes
involved by primary colorectal lesions also had
higher activity, but because of the small number of
nodes examined, the difference from normal nodes
did not reach statistical significance.
Examination of the resected diverticular mass
demonstrated levels of radioactivity comparable to
those obtained from tumours and this would
presumably explain the positive antibody scan.
Confirmation of uptake of radioactivity was
obtained by gamma camera scanning of the
complete resected specimen. A typical scan and the
associated tumour is shown in Figure 3. This is
from a patient with a carcinoma of the fundus of
the stomach who had no lymph node metastases.
The scan clearly demonstrates higher activity
corresponding to the site of the lesion.
The ratios of the counts recorded for the
tumours and the surrounding tissue were 1.9:1 for
gastric cancer, 2.0:1 for colorectal cancer and 1.3:1
for oesophageal cancer. These ratios are lower than
for tumour samples (Table V) reflecting attenuation
of the counts from tissue which was at varying
distances from the gamma camera crystal when the
tumour, which was often rigid, was laid open.
The concentration of antibody within tumours
was estimated in 3 of the resected colonic cancers.
Each had significantly higher levels of radioactivity
than surrounding normal tissue. The proportion of
the injected amount of antibody present was 0.02%,
0.02% and 0.03% respectively. In order to deter-
mine possible cross-reactivity between normal
human immunoglobulin within tumours and the
antimouse immunoglobulin used in the assay, a
tumour sample from a patient who had not
received the labelled antibody was included in the
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Figure 3 Photograph of the specimen (a) and the
specimen scan (b) resected from a patient with
carcinoma of the fundus of the stomach 72h after
infusion of radiolabelled antibody.
ELISA. Although there was minimal cross
reactivity this did not affect the overall percentage
of the injected dose present in the resected tumours.
Intravascular distribution and excretion oflabelled
antibody
Circulating radioactivity showed a biphasic decline.
After 6h 69.5% +30.0 of the administered activity
was detectable. This rapid fall continued such that
by 24h 53.9% +25.5 was present and at 48h
36.9% +23.9 was detectable. The rate of decrease
slowed in the subsequent 24h and by 72h 15.6%
+6.0 was still present.
Antibody concentration, however, showed a more
dramatic decline. At 6h the mean serum
concentration was 2.8ngml-1 or 3.2% of the
injected dose of antibody. By 24h, the mean
concentration was 1.9ngml-1 and by 48h only 3
patients had detectable levels with a mean
concentration of 1.3 ngml.-1
Excretion of radioactivity in the urine throughout
each 24h period was the same: 8.6% +10.6 (day
1), 8.4% +9.0 (day 2) and 7.5% +5.0 (day 3).
Thus 72h after labelled antibody infusion, 25% of
the radioactivity had been excreted.
Excretion in the faeces, however, was minimal.
After 24h 0.09 +0.14 of the injected activity was
excreted and in the second 24h 0.13 +0.16 were
excreted.
Discussion
RIL is potentially a tumour specific method of
investigation. At present because a tumour specific
antigen has yet to be identified, the technique
depends on quantitative differences in the
expression of antigens, such as CEA, between
tumour and normal tissues. In this study we have
evaluated potential clinical roles for RIL in the
management of gastric and colorectal cancer.
Although the scans have been interpreted by one of
the investigators with prior knowledge of the extent
of disease, independent assessment was not
considered of value as not only does the technique
remain to be standardised but potential sources of
error are yet to be eliminated.
The results of the scans are comparable with
reported series. Most of the primary tumours and
the majority of the established recurrences have
been detected. However, the experience of this and
other studies demonstrates that tumour size is a
significant limiting factor. Although some of the
nodal secondary deposits were identified, scanning
resolution was insufficient to allow reliable
detection of small tumour volumes for accurate
preoperative staging or for the detection of early
recurrent disease. This limit of resolution, however,
is no worse than for CT as the comparative study
demonstrates similar numbers of false negative
scans for either modality reflecting the failure to
detect small lesions.
The measurement of radioactivity within tumours
has indicated that both primary and secondary
lesions accumulate more labelled antibody than
surrounding normal tissues. The amount accumu-
lated, however, is so low that detectable contrast
from normal tissues cannot be reliably achievedLOCALISATION OF GASTROINTESTINAL CANCER 209
by external scanning. Attempts to increase the
tumour to normal tissue contrast have evaluated
different isotopes (Fairweather et al., 1983b;
Rainsbury, 1984) and different methods of scanning
such as emission tomography (Berche et al., 1982).
These techniques, however, are methods of im-
proving the sensitivity of the detection of the very
small amounts of labelled antibody accumulated by
tumours. In order for tumour localisation to be
effective for both diagnostic imaging and for drug
targetting, larger proportions of injected antibody
need to be accumulated. Preliminary studies have
demonstrated that combinations of antibodies to
different antigens increase the rate of detection
of tumours presumably reflecting increased uptake
of the injected preparations (Chatal et al., 1984).
Alternatively, increased amounts of antibody to the
same antigen may produce similar results. The
presently available antibodies are not ideal and it
remains to be seen whether more appropriate
antibodies either in combination or in larger doses
will improve the results of tumour localisation.
The pharmacokinetic studies indicate potentially
significant difficulties for the use of mouse
monoclonal antibodies. Previous studies of labelled
autologous gamma globulin have demonstrated a
biphasic clearance over a period of fourteen days
(Myant, 1952). The results of this study for the
vascular distribution of radioactivity are in
concurrence with these studies. However the rapid
clearance of antibody suggests that radioactivity
changes are not a reflection of changes in antibody
levels. The reasons for this apparent discrepancy
are not clear but several factors may be involved.
Firstly detachment of 131I from the antibody may
occur. Approximately 25% of the injected
radioactivity was excreted via the kidneys in the
first 3 days which since all patients had apparently
normal renal function must represent free iodine.
Secondly the mouse monoclonal antibody may
evoke a response in the recipient possibly through
the immune system. There is already evidence that
patients can develop antimouse antibodies (Pimm et
al., 1985b) and these may inactivate or modify the
administered antibody. Alternatively antibody may
become non specifically attached to circulating
cellular components. Whatever the mechanism such
modification would not only influence reactivity
with tumour bound CEA but also would affect the
reaction in the ELISA used to estimate antibody
concentration. Thus the ELISA may not represent
an accurate assessment of the serum or tissue
antibody levels. Further work is in progress to
evaluate any modifications in the antibody and
alternative methods of determining antibody
concentrations.
The technique of tumour localisation by labelled
antibodies has great potential in the assessment of
malignant disease. In this study uptake by primary
and secondary deposits has been demonstrated.
However, the absolute amount of labelled
preparation accumulated is insufflcient to allow
accurate tumour detection and thus limits the
widespread use of the technique in clinical practice.
Further work. with particular reference to the
pharmacokinetics of labelled antibodies is required
to determine whether these difficulties can be
overcome before the technique can be evaluated in
independent clinical trials.
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